While the days of high market growth, driven by the human genome project, are behind us, the era of personal genomics is yet to begin. Next generation genomics technologies are breathing new life into the market, and are expected to contribute to the robust growth of the U.S. genomics market between 2005 and 2012. Top industry participants are successfully developing specific applications for each evolutionary stage of the genomics research process, and are likely to maintain revenue streams, while strategically positioning themselves to penetrate the future markets for clinical applications of genomic technologies.
New analysis from Frost & Sullivan (drugdiscovery.frost.com), Strategic Analysis of U.S. Genomics Markets, reveals that revenues in this market totaled $1.85 billion in 2006, and is likely to reach $3.69 billion in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the Strategic Analysis of U.S. Genomics Markets, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.
“Among the market segments, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) technology, including instrumentation and reagents, is developing as the fastest growing segment of the total U.S. genomics market,” notes Frost & Sullivan Industry Analyst Jonathan Witonsky. “As researchers attempt to validate discoveries made on the foundation of The Human Genome Project, they find technologies such as qRT-PCR ideal for their targeted studies.”
Following the qRT-PCR segment, DNA microarray technology is developing as the second-fastest growing segment of the total U.S. genomics market. While genome-wide expression analyses are forecasted to drive the majority of DNA microarray segment growth, markets related to novel genomics analyses, such as comparative genomic hybridization (CGH), genome-wide methylation studies, and chromatin immunoprecipitation (ChIP)-chip, are likely to see the highest growth. Finally, the majority of the DNA sequencing technology segment growth is anticipated to result from the introduction and extensive placement of next generation DNA sequencing technologies.
Despite these positives, genomics platforms that are too inefficient and expensive for ultra-high throughput comprehensive genome-wide analysis are hindering the realization of personal genomics. Moreover, the markets for last-generation genomics technologies, such as general polymerase chain reaction (PCR) and conventional DNA sequencing, are beginning to stabilize.
“Conventional genomics technologies require a considerable amount of time to operate and cost too much per analysis for the types of genomics studies that are expected to ultimately transform biomedical research, and, subsequently, molecular diagnostics, pharmacogenomics, drug discovery and development, and personalized medicine,” says Witonsky. “The lack of efficiency and cost-effectiveness of conventional genomics technologies prevent full fledged utilization that could drive revenue growth.”
While numerous initiatives continue to support the application of multiple genomics technologies, market participants must strategically position their genomics technologies with applications that enable customers to make a smooth research transition from discovery to validation.
Strategic Analysis of U.S. Genomics Markets is part of the Drug Discovery Technologies Subscription, which also includes research in the following markets: U.S. sequencing services markets, U.S. DNA microarray markets, U.S. microfluidics/lab-on-a-chip markets, U.S. nucleic acid isolation markets and U.S. RNAi markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews are available to the press.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.